Browse Articles

Discover research articles across all indexed journals

Overall survival between veterans with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone with kidney disease.

Journal of Clinical Oncology Robert Wilson, Jason M Doherty, Suhong Luo et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.76

76 Background: Enzalutamide and abiraterone are androgen receptor pathway inhibitors (ARPIs) used in metastatic castration-resistant prostate cancer (mCRPC). However, little research has compared their efficacy in this population with co-morbid chronic kidney disease (CKD). Since these medications alter androgen signaling differently and abiraterone is co-administered with prednisone, median overall survival (OS) may differ in patients with decreased renal function. Methods: Veterans within the Veterans Health Administration initially treated with abiraterone or enzalutamide for mCRPC between September 8, 2014, and October 9, 2023 were included. Age at treatment initiation, PSA at diagnosis, race, Charlson comorbidity index, and baseline serum creatinine values were acquired for each patient. Patients with an estimated glomerular filtration rate (eGFR) less than 60 mL/min were included in the CKD group. Survival analysis was performed using the Kaplan-Meier method. Cox proportional hazards modeling was used to adjust for differences in baseline characteristics between study groups. Results: We analyzed 10,356 veterans with mCRPC. 1944 (18.8%) had an eGFR less than 60 mL/min and 8412 (81.2%) had an eGFR greater than or equal to 60 mL/min. Of the CKD group, 1093 (56.2%) were treated first with abiraterone and 851 (43.8%) with enzalutamide. The enzalutamide group contained a larger percentage of patients with both cardiovascular disease and diabetes mellitus (47.7% vs. 40.4%, p = 0.06). The abiraterone group had a higher median PSA at diagnosis (7.2 vs 3.9 ng/mL, p < 0.001) and lower median eGFR at treatment initiation (48.82 vs. 49.32 mL/min, p = 0.03). There was no significant difference in median OS between patients treated with abiraterone (n = 4752) or enzalutamide (n = 3660) in the group of patients without CKD (42.9 vs. 44.0 months, p = 0.29). However, in the group of patients with CKD, enzalutamide revealed a longer median OS (35.2 vs 30.5 months, p < 0.001) and decreased mortality when adjusting for differences in baseline characteristics (Adjusted HR 0.80, 95% CI 0.77-0.94). Additionally, patients with CKD were able to take enzalutamide for a longer duration than abiraterone (11 vs. 7 months, p < 0.001). Conclusions: In Veterans with CKD, enzalutamide exhibited longer median OS and decreased risk of death relative to abiraterone. Further research into treatment selection based on comorbid disease could generate revised clinical guidelines that optimize survival in patients with mCRPC. Survival Time Hazard Ratio with 95% CI Adjusted Hazard Ratio with 95% CI CKD Group (n=1944) Enzalutamide (n=851): 35.2 monthsAbiraterone (n=1093): 30.5 monthsp < 0.001 0.835 (0.754 - 0.926) 0.849 (0.766 - 0.941) Non-CKD Group (n=8412) Enzalutamide (n=3660): 44.0 monthsAbiraterone (n=4752): 42.9 monthsp = 0.29 0.944 (0.899 - 0.998) 0.947 (0.899 - 0.998)

Ecological vulnerability and driving factors in the himalayan transboundary landscape under global climate change

Scientific Reports Kun Zhu, Yiwei Zhu, Zhenyu Zhao et al. Feb 10, 2025 DOI: 10.1038/s41598-025-86811-4

PET imaging for metastatic castration sensitive prostate cancer (mCSPC) for patients with PSA response after systemic therapy: A multicentric ambispective analysis.

Journal of Clinical Oncology Mathilde Beaufils, Lucie Meynard, Alice Bernard-Tessier et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.37

37 Background: PET imaging is not recommended for surveillance of mCSPC but it is used by some physicians. Little is known about surveillance for metastatic prostate cancer using PET imaging. The aim of this study was to assess the correlation between PSA response and PET imaging for mCSPC. Methods: An ambispective, multicentric, observational study, recorded PET imaging for patient’s treated with a minimum of 6 months of systemic therapy with androgen deprivation therapy (ADT) +/- androgen receptor pathway inhibitor (ARPI) +/- docetaxel for mCSPC with PSA < 0.2 ng/ml, normal CT scan and non progressive disease in bone scan. All of them had baseline evaluation with standard imaging. Results: Between August 2022 and September 2024, 57 patients (pts) with mCSPC were included, in 4 centres in France. Baseline characteristics at the time of metastatic disease were: median age of 65 years (range: 45-84), ISUP ≥4 for 63%, median PSA 22.1 ng/ml (1.6-5000ng/ml) with T≥3 in 53%. The majority of pts had low volume disease 56%, with synchronous metastatic disease for 67% and ≥ 4 bone metastases in 44%. Only 5 pts had visceral metastases. Pts were treated, by ADT + ARPI in 81%, ADT + docetaxel in 7% and triplet in 12% of cases. Patients had prostate radiotherapy (RxT) in 39% and RxT to metastatic bone lesion in 19%. The 8 months PSA was <0.2 ng/ml in 89% of pts. PET imaging was choline in 86%, PSMA in 14%. Median time between treatment initiation and PET imaging was 17 months and delay between PSA < 0.2 and PET imaging was 12 months (range: 0-32). A complete response was observed in 46 patients (81%). Non-complete responders (CR) were more frequently high volume disease (66%) and synchronous metastasis (100%), treated by ADT + ARPI alone (77%) or ADT + docetaxel (11%). Non CR were: 1 neuroendocrine progression, 1 lung cancer and 9 partial responders (2/9 progressed later). Conclusions: In patients with mCSPC, treated by ADT with ARPI and or docetaxel and with PSA < 0.2 ng/ml, a complete response is observed in 81 % when using PET imaging. The information given by PET imaging could be and additional surrogate measure to PSA response for intensification or de intensification the systemic and local treatment for mCSPC.

Evaluation of the impact on overall survival curves of patients with metastatic castration-sensitive prostate cancer staged with PET-PSMA and classified according to current prognostic criteria by volume and risk.

Journal of Clinical Oncology Isadora Martins de Sousa, Luciana de Moura Leite, André Marcondes Braga Ribeiro et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.36

36 Background: The treatment of metastatic castration-sensitive prostate cancer (mCSPC) has evolved over the years. These therapies are guided by current volume (CHAARTED) and risk (LATITUDE) criteria, instituted based on conventional exams. The emergence of new imaging exams like PSMA PET, with its greater accuracy and early detection of metastatic disease, raises questions about the applicability of these criteria in this context. Methods: We conducted a retrospective, single-center study comparing patients staged with PSMA PET between August 2017 and February 2022 and classified as metastatic, after curative therapy or de novo metastatic. Patients with stage IVA, i.e., N1, were also included. Patients were stratified into high and low volume and risk, with the aim of comparing these prognostic factors with outcome of OS. Results: 48 patients with a median age of 66 years at diagnosis were selected: 81.3% had Gleason scores between 8 to 10, 57% had T classification greater than or equal to T3 and 32% were N1 by conventional exams. According to PSMA PET, 40% were de novo metastatic, with disease sites being bones (M1b - 52%), non-pelvic lymph nodes (M1a - 21%), pelvic lymph nodes (N1 - 17%), and viscera (M1c - 10%). 71% of them were low volume and 75% were low risk. With a median follow-up of 37.5 months and 7 deaths, at 36 months we had 64.6% of the high-volume population alive versus 96.6% of low-volume patients (p=0.054), 77.8% of high-risk patients alive compared to 89.9% of low-risk ones (p=0.739). There was a 67% increase in distant metastasis detection. When correlated with bone scintigraphy (BS), there was a 78.9% discordance between the number and/or location of bone lesions, and in 53.3% of cases, PSMA PET was positive for bone disease with negative BS at the same time. Conclusions: PSMA PET appears to be prognostic when applied to volume curves, despite p=0.054, which does not happen for risk, in addition to increasing the detection of metastatic disease compared to conventional exams and being more accurate in the detection of bone disease when compared to BS.

Prevalence of FGFR3 p.Arg248Cys mutation in lynch syndrome associated urothelial carcinoma: A single institution dataset.

Journal of Clinical Oncology Alessandro Rametta, Marco Vitellaro, Marco Barella et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.858

858 Background: Patients with Lynch syndrome have an increased risk of developing UC and a relative risk in patient with MSH2 germline impairment of 3,6. In 2024, kinase-inhibitor erdafinitib has been approved in FGFR3 mutated locally advanced and metastatic UC. The aim of the study is to molecularly characterize Lynch-syndrome associated UC (LS-UC). Methods: Starting from a single-institution dataset of patients with Lynch syndrome, we identified 24 patients with LS-UC, of which 13 cases had available specimen for molecular analysis. A DNA NGS analysis was performed with a Cancer Hot-Spot Panel (Thermo Fisher Scientific) covering 50 genes, the detection of fusion transcripts was carried out by RNA-based Oncomine Comprehensive Assay Plus (Thermo Fisher Scientific). Specimen, which didn’t pass internal quality control, were excluded. Results: Our case set was composed of 4 (31%) renal pelvis UC, 4 (31%) ureter UC and 5 (38%) bladder UC and germline pathogenetic variant (GPV) was detected in MSH2 in 7/13 (54%) patients, in MSH6 in 4/13 and in MLH1 in 2/13. Nine specimen provided evaluable material for molecular analysis. No gene fusions were detected in examined genes. The most frequent altered gene was FGFR3 in 6 (46%) cases. In one case, p.Glu368Lys mutation was observed, which is classified as variant of uncertain significance. In five cases (38%), we found the pathogenic variant p.Arg248Cys, which is set near the most frequent alteration in FGFR3 gene in sporadic UC (p.Ser249Cys) and is associated with a good response to erdafinitib. No differences were observed between cases with pathogenic FGFR3 mutation and other cases in term of GPV, tumor site, histologic grade and relapse. Among p.Arg248Cys FGFR3 mutated UC, 4/5 were upper tract UC and 1/4 was bladder UC, four carcinomas were high grade and one was low grade. At surgery time, 2/5 were locally advance with lymph node metastasis and both had a lymph node relapse within 24 months. Conclusions: Despite the small sample size, we confirmed a prominent relation between MSH2 germline mutation and the development of UC. Moreover, we observed a clear preponderance of p.Arg248Cys mutation in FGFR3 mutated LS-UC. These data shine a spotlight on druggable mutation in LS-UC, suggesting a role for molecular analysis in the therapeutic algorithm of these patients. Case Sex Pathogenic Variant Site FGFR3 mutation Other Pathogenic Mutation T N Grade 1 F MSH2 Renal Pelvis x x T1 NX LG 2 M MSH6 Bladder x x Ta NX LG 3 M MSH2 Ureter FGFR3 p.Glu368Lys (VUS) SMARCB1 T3 N0 HG 4 F MSH2 Bladder FGFR3 c.742C>T PIK3CA, TP53, RB1 pT1e NX HG 5 F MSH2 Renal Pelvis FGFR3 c.742C>T PIK3CA Ta NX LG 6 F MSH6 Bladder - TP53 T1 NX HG 7 M MLH1 Ureter FGFR3 c.742C>T - T2 N1 HG 8 F MSH2 Renal Pelvis FGFR3 c.742C>T ARID1A T3 N2 HG 9 F MSH6 Bladder x x T1 NX HG 10 M MSH2 Bladder x x T1 NX HG 11 F MSH2 Renal Pelvis - MSH2, BARD1, NF1, SMARCA4 T4 N0 HG 12 M MSH6 Ureter FGFR3 c.742C>T PIK3CA T1 N0 HG 13 M MLH1 Ureter - FBXW7, PTPN11 x x x

Comparative performance of multiple ensemble learning models for preoperative prediction of tumor deposits in rectal cancer based on MR imaging

Scientific Reports Jiayi Wang, Fayong Hu, Jin Li et al. Feb 10, 2025 DOI: 10.1038/s41598-025-89482-3

Impact of testosterone recovery after androgen deprivation therapy on overall survival in patients with high-risk prostate cancer: Long-term data from a phase III trial.

Journal of Clinical Oncology Abdenour Nabid, Nathalie Carrier, Andre-Guy Martin et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.310

310 Background: To determine the potential impact of persistent hypogonadism on overall survival (OS) after prolonged androgen deprivation therapy (ADT) in patients (pts) with high-risk prostate cancer. Methods: From 10/2000 to 01/2008, 630 pts were randomised to pelvic radiotherapy (RT) plus 36 (310 pts) vs. 18 months (320 pts) of ADT. Serum testosterone (T) was prospectively collected at baseline, then regularly. We defined T recovery as a return of T to within the normal range value of each participating institution, regardless of whether it was initially normal or abnormal. Excluded from the analysis were pts not receiving exactly 18 or 36 months of ADT (48), or had no T measured at baseline or during follow-up (67). We compared OS between patients recovering or not T to a normal level using the log rank test. Multivariable analysis to predict OS included recovered T to a normal level, age, Zubrod, comorbidities, baseline PSA, Gleason score, stage and ADT duration. Results: 515/630 pts had proper T data available (baseline and follow-up) and were retained for the analysis. The results are reported with a median follow-up of 17.4 years. Over a period of 22 years, 6587 T measurements were available. A total of 270/515 pts (52.4%) recovered T to normal level, 188/330 (57%) in the 18-month and 82/185 (44.3%) in the 36-month cohort, p=0.006. Pts not recovering T to a normal level were older, had higher clinical stage and diabetes. Among pts regaining T to a normal level, the median time to T recovery was 3.6 (IQR 2.9-4.9) years.10- and 15-year OS rates were 76% (71-81) and 44% (38-51) for pts recovering T vs. 55% (49-62) and 30% (24-36) for those who did not, p<0.001. A significant lower risk of death favoured pts recovering T when considering the global hazard ratio (HR) [HR (95% CI) = 0.54 (0.44-0.67), p<0.001]. Significant differences in HR for death are maintained for both 18-month [HR = 0.51 (0.39-0.66), p<0.001] and 36-month cohort [HR = 0.58 (0.40-0.84), p=0.004]. In multivariable analyses, the impact of T recovery remains significant for the risk of death [(HR = 0.69 (0.55-0.86), p=0.001], and also for the 18-month [HR = 0.70 (0.53-0.93), p=0.013] and the 36-month cohort [(HR = 0.61 (0.40-0.93), p=0.021]. In a multivariable model, among pts regaining T to a normal level, the time to T recovery had no impact on OS [HR = 0.97 (0.90-1.04), p=0.41]. Of note, there was no significant difference in the rate of death from prostate cancer between pts recovering or not T (11.9% vs. 13.5%, p=0.58). Competing risk analysis confirms this finding [sHR = 0.83 (0.51-1.35), p=0.57]. Conclusions: In high-risk prostate cancer treated with RT and long-term ADT, T recovery to normal level is associated with a significant improvement in overall survival. The increased death rate in pts not recovering T is likely due to causes unrelated to prostate cancer. Clinical trial information: NCT00223171 .

Comparison of digital pathology AI models, genomics classifier, and clinical variables in predicting progression free survival in TCGA prostate data set.

Journal of Clinical Oncology Aidan McLoughlin, Alboukadel Kassambara, Ho Yin Ho et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.335

335 Background: Recent advances in AI have brought innovation to digital pathology problems with H&E whole slide images (WSI). Though some digital pathology AI (DPAI) models have been developed for survival analysis with TCGA data, there is a lack of understanding as to how DPAI models predict progression free survival (PFS) in the TCGA prostate dataset (PRAD). Nor is there a comprehensive comparison of DPAI models versus genomic or clinical models. Batch effects were also ignored in prior works. Methods: PRAD contains 392 patients with WSI and clinical data. WSI batch effect was first evaluated with HistoQC (1). We trained 4 different DPAIs to predict PFS in five-fold cross-validation (CV), controlling for the batch effects in the data splits. Such CV was repeated five times under different random splits. Each model’s performance was evaluated with mean C-index, whose confidence interval (CI) was approximated by the second smallest to the second largest value from the 25 splits. The same evaluation was used for the clinical or genomic model trained with regularized Cox regression. The clinical-only model used variables of age, Gleason group, and adverse pathology features. The genomic model was trained using expression of five prognostic genes from Mou et al. 2022. Multi-modal models using clinical variables with expression and/or DPAI features were evaluated in the same way. Results: Substantial WSI batch effects were discovered across the PRAD dataset; we excluded 9 patients whose WSIs were generated with a distinct scanner. With the remaining 383 patients, the clinical-only model achieved a mean C-index of 0.73 (0.63, 0.84) in the cross-validations, compared to that of 0.72 (0.58, 0.88) by the expression-only model. The clinical-genomic model achieved a better performance of 0.79 (0.65, 0.90). Among the DPAI models, CLAM attention model (2) initialized under the UNI foundation model (3) achieved best mean C-index of 0.68 (0.57, 0.82). Combining this DPAI model with clinical variables achieved a modestly larger C-index of 0.71 (0.59, 0.83). Interestingly, adding gene expression to this multi-modal model didn’t further improve performance. We also observed that ignoring batch effects during data-splitting consistently worsens performance. Conclusions: To the best of our knowledge, this is the first deep dive into PFS prediction on PRAD comparing DPAI with clinical or expression-based models. All modalities of data yielded similar C-indices with overlapping CIs, while the clinical-genomic model performed best. Controlling batch effects is important for DPAI models; future research is needed to explore if batch effect correction on WSI can bring DPAI’s performance closer to clinical-genomic models. Larger sample size is needed to adequately compare data modalities or build proper multi-modality models. 1. Janowczyk et al. 2019. 2. Lu, et al. 2020. 3. Chen, et al. 2023.

KIM-1 as a circulating biomarker in metastatic RCC: Post-hoc analysis of JAVELIN Renal 101.

Journal of Clinical Oncology Marc Machaalani, Renee Maria Saliby, Caiwei Zhong et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.594

594 Background: Kidney injury molecule-1 (KIM-1) is a circulating biomarker for renal cell carcinoma. The JAVELIN Renal 101 trial established avelumab and axitinib as a standard treatment regimen for advanced renal cell carcinoma (aRCC). In this post-hoc analysis, we evaluated whether baseline plasma KIM-1 and KIM-1 change on treatment are associated with outcomes in JAVELIN Renal 101. Methods: Patients with aRCC were randomized to avelumab plus axitinib (Av/Ax) or sunitinib (Sun), as previously described. KIM-1 was measured in plasma at baseline (C1D1) and at C3D1 using a Luminex microbead-based assay and an MSD electrochemiluminescence-based assay. KIM-1 values were categorized into high and low according to an optimized cutoff based on the maximum log-rank Q-statistic for PFS. Cox regression analyses were performed for OS and PFS and adjusted for baseline clinical characteristics. Associations between KIM-1 levels and clinical and transcriptomic data were evaluated using the Wilcoxon rank-sum test. Results: Plasma for analysis was available from 612 patients (69% of the ITT population), including 323 treated with Av/Ax and 289 with Sun. 57% of patients had high KIM-1 at baseline. In all patients, lower circulating KIM-1 at baseline was associated with longer progression-free survival (PFS) and overall survival (OS) (Table). Baseline KIM-1 levels were significantly lower in angiogenic (1-2) vs immune (4-5) transcriptomic clusters (p=0.002), responders vs non-responders (p=0.01), and exceptional vs intermediate responders (p=0.0015). In paired analyses, circulating KIM-1 decreased from baseline to C3D1 (p<0.0001) in both arms. Decrease in KIM-1 from baseline to C3D1 was associated with longer PFS and OS (Table). Luminex and MSD antibody-based assays had good concordance for distinguishing higher vs lower KIM-1 when measured in the same samples (Spearman’s ρ = 0.737), but absolute values of KIM-1 differed between the two assays (p<0.0001). Conclusions: This is the first study to evaluate circulating KIM-1 among patients with aRCC receiving immune checkpoint inhibitor and VEGF tyrosine kinase inhibitor combination therapy. Lower baseline plasma KIM-1 and decrease during treatment were associated with better prognosis. The distribution of circulating KIM-1 is assay-dependent and standardized cutoffs are needed before KIM-1 can be used in clinical decision making. Association of baseline KIM-1 and KIM-1 change on treatment with outcomes. Entire CohortHR (95% CI) SunitinibHR (95% CI) Avelumab + AxitinibHR (95% CI) PFS(KIM-1 low vs high) 0.76 (0.58–0.99) 0.67 (0.47–0.95) 0.88 (0.61–1.28) OS(KIM-1 low vs high) 0.58 (0.38–0.88) 0.46 (0.26–0.81) 0.79 (0.43–1.47) PFS(KIM-1 decrease vs increase) 0.65 (0.46–0.87) 0.66 (0.46–0.96) 0.79 (0.48–1.30) OS(KIM-1 decrease vs increase) 0.58 (0.39–0.88) 0.79 (0.46–1.35) 0.45 (0.46–0.89) HR: hazard ratio; CI: confidence interval.

Prediction of COVID-19 cases by multifactor driven long short-term memory (LSTM) model

Scientific Reports Yanwen Shao, Tsz Kin Wan, Kei Hang Katie Chan Feb 10, 2025 DOI: 10.1038/s41598-025-86698-1

A phase 1, first-in-human, open label, dose escalating study of B440, an oral cancer vaccine using a WT1-expressing <i>Bifidobacterium</i> , in patients with advanced urothelial cancer.

Journal of Clinical Oncology Toshiro Shirakawa, Junya Furukawa, Yasumasa Kakei et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps883

TPS883 Background: B440, an oral cancer therapeutic vaccine, is based on an innovative oral vaccine platform utilizing gut microbiota ( B. longum; Bifidobacterium longum ) that can efficiently deliver the heterogeneous antigen protein to dendritic cells (DCs) in Peyer's patches in gut-associated lymphoid tissue (GALT). B440 is a lyophilized powder of inactivated B. longum 440, a recombinant B. longum expressing a partially modified human WT1 tumor-associated antigen protein (amino acids 117-419 with a single amino acid substitution at 236 from M to Y to enhance immunogenicity). In preclinical studies, B440 showed superior anti-tumor activity to the WT1 peptide vaccine (WT1 126-134 peptide, human HLA-A02 or mouse H-2Db restricted CD8 epitope) due to the large length of the WT1 117-419 protein, including multiple CD8 and CD4 epitopes without HLA restriction, and its ability to internalize into DCs (1, 2). Furthermore, our extensive preclinical studies showed that B440 alone or as an adjunct to an anti-PD1 antibody can induce potent WT1-specific cellular immunity and anti-tumor activity in several mouse syngeneic tumor models (urothelial cancer (3), prostate cancer (4), and renal cell carcinoma (5)). Methods: This first-in-human, multicenter, open-label, single-arm, investigator-initiated phase 1 study will evaluate the safety and initial efficacy of B440 monotherapy in patients with advanced urothelial cancer who are refractory to all standard therapies, including chemotherapeutic agents, PD-1/PD-L1 inhibitors and antibody-drug conjugates (ADCs). A total of 12 patients will receive B440 orally once daily for 5 consecutive days followed by a 2-day rest for a total of 20 doses for 4 weeks. The study consists of 2 escalating doses of 6 patients each; the low dose group will receive 800 mg (4 capsules) per dose and the high dose group will receive 1,600 mg (8 capsules) per dose. One enteric capsule contains 200 mg of B440, equivalent to 2X10 10 colony forming units (cfu) of B. longum 440. The primary endpoint is the determination of dose-limiting toxicity (DLT) with an assessment period of 4 weeks during treatment. Secondary endpoints are safety as assessed by adverse events (AEs) using CTCAE 5.0 and efficacy as assessed by best overall response and progression-free survival (PFS) using RECIST ver1.1. In addition, the immunological response to B440 will be evaluated by enzyme-linked immunosorbent assay (ELISPOT). The study was registered with the Japan Registry of Clinical Trials under the number jRCT2051220143 on December 27, 2022. Patient enrollment was completed in September 2024. Research Sponsor: Immunorock Co., Ltd., Grant: the Japan Agency for Medical Research and Development (AMED); 23ym0126081h0002. Clinical trial information: jRCT2051220143 .

The impact of neoadjuvant therapy on the formation of tertiary lymphatic structures and the distinct prognosis in prostate cancer.

Journal of Clinical Oncology Shengzhuo Liu, Jing Zhou, Xin Yan et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.411

411 Background: This study aims to investigate the characteristics and prognostic predictive efficiency of tertiary lymphoid structures (TLS) in prostate cancer (PCA). We also perform experiments to explore the effects of neoadjuvant hormone therapy (NHT) on TLS formation and immune infiltration in PCA. Methods: We retrospectively collected paraffin-embedded tumor tissue samples from 27 patients who didn`t receive NHT and underwent radical prostatectomy for PCa, and these patients were categorized as Cohort 1. We Additionally retrospectively collected 28 PCa tumor samples, from 14 NHT treated and 14 NHT naive patients, which are categorized as Cohort 2. We prospectively collected prostate biopsy tissue samples, as well as corresponding radical prostatectomy tumor specimens, from 21 patients who all received NHT and are categorized as Cohort 3. We performed HE staining and Multiplex immunohistochemical (mIHC) staining for ki67, panCK, CD21, CD4, CD8, and CD20 to evaluate TLS characteristics and immune infiltration level in different cohorts. We enrolled two GEO cohorts to evaluate the difference of TLS signature between NHT treated PCA and NHT-Naive PCA patients, and between pre-NHT and post-NHT tumor paired samples. We developed an immunocompetent orthotopic prostate cancer mouse model based on CRISPR-Cas9 gene editing technology. In in vivo experiments, we utilized flow cytometry to investigate the difference of CD4 and CD8 immune cell infiltration level in tumor tissues of mice treated or not with androgen deprivation treatment. Results: We found most of the NHT-naive PCa tissues were TLS positive (93%), and the majority of TLSs are located within the tumor region. Patients with positive mature TLSs, SFL-TLSs and higher intra-tumor TLSs density had significantly longer PFS duration. Compared with that in patients received no NHT, TLSs maturity grade and density were higher in NHT treated patients. A matched analysis using biopsy and paired post-NHT tumor samples revealed that NHT significantly increased the positive detection rate of tertiary lymphoid structures (TLSs) within the tumor, the maturity grade of TLSs, and the level of CD8+ T cell infiltration within the TLSs. Transcriptome analysis revealed elevated TLSs signature expression and CD8+ T cell infiltration in NHT treated tumor samples. In vivo experiments also show elevated CD3+ and CD8+ T cells infiltration level after NHT treatment. Conclusions: This study comprehensively characterizes TLSs in PCa and highlights the heterogeneity among patients. Our clinical cohort data, transcriptome sequencing analysis, and in-vivo experiment data confirm that neoadjuvant hormone therapy promotes immune cell infiltration, as well as the formation and maturation of TLSs within PCa tissues. Combining endocrine therapy with immunotherapy is a potential treatment approach for promoting prostate cancer prognosis.

Neoadjuvant combined chemotherapy and immunotherapy for upper tract urothelial carcinoma: Preliminary results from a phase II study.

Journal of Clinical Oncology Xingang Bi, Wen Zhang, Yaoyu Xie et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.812

812 Background: Upper Tract Urothelial Carcinoma (UTUC) presents a challenging prognosis even after Radical Nephroureterectomy (RNU). The efficacy of neoadjuvant chemotherapy for UTUC remains uncertain.This phase II study aims to investigate the efficacy and safety of a combination of chemotherapy (Gemcitabine/Cisplatin/Carboplatin) and PD-1 inhibitor (Toripalimab /Tislelizumab/Nivolumab) as neoadjuvant treatment (NT) in UTUC patients. Methods: We planned to enroll 34 UTUC patients with either cT1N0M0 (high grade) or cT2-3N0M0, confirmed by ureterorenoscopy biopsy and imaging. The treatment regimen included three or four cycles of NT (Gemcitabine, 800mg/m 2 , days 1 and 8/Cisplatin or Carboplatin, 60mg/m 2 , day 1/Toripalimab or Tislelizumab or Nivolumab, 240mg, day 1 of a 21-day cycle), followed by RNU and pelvic lymphadenectomy. The primary outcome was the pathological complete response (pCR) rate, with secondary outcomes including significant downstaging (≤pT1) rate, disease control rate (DCR), and safety. Results: To date, 30 patients have been accrued since August 1st, 2020, and recruitment is ongoing. Twenty-seven patients have completed treatments and were preliminarily analyzed, with three patients still undergoing treatment. The median age was 65.0 years, with 55.6% being male. The majority of patients had unifocal tumors, with a median maximum diameter of 3.3cm (0.7-7.5). All patients experienced obstructed hydronephrosis. Clinical T staging was confirmed by multi-parameter MRI, indicating four T2 and twenty-three T3 patients. Ureterorenoscopy biopsy revealed twenty-five high-grade and two low-grade urothelial carcinoma patients. All patients were classified as high-risk UTUC. Twenty patients completed 4 cycles, five underwent 3 cycles and two underwent 2 cycles. The median interval time from initiation of NT to RNU and from the end of NT to RNU was 17.3 (11.4-28) weeks and 6.8 (2.3-22) weeks respectively. The pCR rate was 29.6% (8/27), the ≤pT1 rate was 63.0% (17/27), and the DCR was 100%. No grade 4-5 chemotherapy-related adverse events were recorded, but 41% (11/27) experienced grade 2 myelosuppression, 29.6% (8/27) grade 3, and 7.4% (2/27) grade 4. Four patients experienced immune-related adverse events after 4 cycles, including hypothyroidism (grade 2) and adrenal insufficiency (grade 2). No surgery-related complications or readmissions within one month were reported. With a median follow-up of 14.1months, all patients remained alive and tumor-free. Conclusions: Preliminary analyses suggest that the combination of chemotherapy and a PD-1 inhibitor as NT exhibits promising pCR rate for UTUC. The treatment was manageable in terms of safety, with immune-related adverse events potentially leading to prolonged treatment periods. Clinical trial information: NCT04099589 .

Sex differences in the association between serum α-Klotho levels and hyperlipidemia: a cross-sectional study from NHANES 2013–2016

Scientific Reports Yu Han, Chao Liu, Ying Nie et al. Feb 10, 2025 DOI: 10.1038/s41598-024-85018-3

A phase 1/2 study of detalimogene voraplasmid (EG-70) intravesical monotherapy for patients with high-risk non-muscle invasive bladder cancer (NMIBC).

Journal of Clinical Oncology Shreyas Joshi, Sam S. Chang, Rian J. Dickstein et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps886

TPS886 Background: High-risk NMIBC is generally treated with adjuvant intravesical bacille Calmette-Guérin (BCG); however, ~50% of patients experience recurrence and/or progression after BCG and are considered unresponsive. Detalimogene voraplasmid (EG-70) is an investigational, intravesically administered therapy designed to elicit local stimulation of anti-tumor immune responses in the bladder and drive durable efficacy in BCG-unresponsive NMIBC, while mitigating the risk of systemic toxicities from immune stimulation. The Phase 1 (dose-escalation) portion of the first-in-human Phase 1/2, open-label, multicenter study (LEGEND; NCT04752722) of detalimogene voraplasmid is complete. The Phase 2 dose was identified, treatment was generally well tolerated, and the overall complete response (CR) rate was 73% [Kalota S, et al. AUA 2024]. Here we describe the ongoing Phase 2 portion of the study, which opened to enrollment in May 2023; a new cohort of papillary only (no carcinoma in situ [CIS]) disease is being included. Methods: Eligibility criteria: age ≥18 years; ECOG PS 0−2; NMIBC, with/without resected coexisting papillary tumors, ineligible for, or elected not to undergo, cystectomy; satisfactory bladder function. Patients receive detalimogene voraplasmid 0.8 mg/mL in 50 mL (intravesical administration, Weeks 1, 2, 5 &amp; 6, 12-week cycle) for 4 cycles: BCG-unresponsive with CIS (Cohort 1); BCG-exposed or BCG-naïve with CIS (Cohort 2); BCG-unresponsive with high-grade papillary bladder cancer without CIS (Cohort 3). Phase 2 primary endpoints: efficacy (CR rate at Week 48); safety. Secondary endpoints: progression-free survival; CR rate at Weeks 12, 24, 36, and 48; duration of response. The study is being conducted in accordance with the ethical principles of the Declaration of Helsinki and is consistent with ICH/GCP. All patients provide written informed consent. The Phase 2 portion of the study is enrolling and will recruit up to 300 patients from sites in the USA, Canada, Europe, and the Asia-Pacific region. Clinical trial information: NCT04752722 .

A survival prediction model for veterans with advanced bladder cancer (BC) treated with immune checkpoint inhibitors (ICI).

Journal of Clinical Oncology Daniel Sabater Minarim, Kylie Margaret Morgan, Leah N. Deshler et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.855

855 Background: ICIs have been associated with improved survival for patients with BC and are now an integral part of the treatment paradigm. However, predictive biomarkers for ICI in BC have not been established. Here we report outcomes for veterans with BC treated with ICI and evaluate a prediction model based on clinical and genomic characteristics. Methods: We analyzed a cohort of 456 patients with BC treated with single agent anti-PD1/PDL1 therapies from 2019 to 2024 in the VA Informatics and Computing Infrastructure (VINCI) database, and also received FoundationOne CDx testing. Genomic analysis included gene mutations, copy number variants (CNV), and key biomarkers such as PDL1 CPS expression, and tumor mutational burden (TMB). PDL1 expression was stratified into high (&gt;10) and low (&lt;=10); TMB was stratified high (&gt;=10) or low (&lt;10). Genes and CNVs mutated in at least 5% of the population were used in univariate cox proportional hazards models predicting for overall survival (OS). Significant genes (p&lt; 0.2) were then incorporated in a multivariate model adjusting for current biomarkers and demographic variables. OS analyses were conducted from the first immunotherapy to death or last follow-up date utilizing the cox proportions hazard model. Model performance before and after removing the significant genes was compared by concordance index with ANOVA. Results: In this cohort, the median follow-up time for patients alive was 17.5 months. The 2-year OS was 41.6% and the median time on treatment was 4.1 months. Gene mutations with a statistically significant association with OS in univariate analysis included: ERBB2 amplification, CDKN1A, CDKN2A.B loss, TP53, TERT promoter, ARID1A, FGFR3, CREBBP, and TRADD. In the multivariate analysis, low PDL1 expression (hazard ratio [HR] 1.82 95% confidence interval [CI] 1.26-2.64, p&lt;0.005), TP53 mutation (HR 1.60, 95% CI 1.18-2.60, p&lt;0.005), CDKN1A mutation (HR 1.66, 95% CI 1.06-2.61, p=0.02), and TERT mutation (HR 1.64, 95% CI 1.15-2.34, p=0.006) were significantly associated with decreased OS. Patients with FGFR3 wild type mutation were significantly associated with increased OS (HR 0.63, 95% CI 0.41-0.95 p=0.02). High TMB did not meet statistical significance for OS (HR 0.75, 95% CI 0.56-1.01, p=0.06). When all factors are included in the multivariable model the concordance index is 0.67. Conclusions: We report outcomes for veterans with BC treated with ICI. We highlight that PDL1 expression was associated with improved OS, while TMB did not meet statistical significance. We further highlight genomic variants that were associated with OS outcomes for patients with BC on ICI and propose a multivariable model. Current efforts are focused on training and validating machine learning algorithms to predict outcomes for patients with BC treated with ICI and ICI-combinations.

Association of androgen deprivation therapy and acute kidney injury in patients with prostate cancer: A systematic review and meta-analysis.

Journal of Clinical Oncology Gustavo Franco Carvalhal, Iago Pires, Renan Yuji Ura Sudo et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.111

111 Background: Androgen deprivation therapy (ADT) has been associated with cardiovascular risk in prostate cancer patients. Thus, we performed a systematic review and meta-analysis to assess the incidence of acute kidney injury (AKI) in prostate cancer patients under ADT. Methods: PubMed, Embase, and Cochrane Library were searched from inception to October 2024. A random-effects model was employed to compute mean differences for continuous endpoints. Heterogeneity was evaluated by prediction interval and I-squared statistics. All statistical analysis was conducted using R software 4.4.1. GRADE approach rated the certainty of the evidence and the results were reported following the PRISMA statement guidelines. Results: Four studies involving 72,980 patients with a mean age of 73.5 years were included. Over a mean follow-up of 6.7 years, ADT was associated with an increase in the AKI incidence in prostate cancer patients compared to patients not receiving ADT (RR 1.34; 95% CI 1.13-1.58; p&lt;0.001). Among patients who developed AKI while receiving ADT, the use of GnRH agonists was not associated with AKI incidence (RR 4.32; 95% CI 0.60-30.97; p=0.146). Similarly, when comparing AKI risk between patients on GnRH agonists alone and those without ADT, no statistically significant difference was found (RR 1.24; 95% CI 0.73-2.11; p=0.424). Orchiectomized patients had a lower AKI incidence than GnRH agonist users (RR 1.16; 95% CI 1.04-1.3; p=0.009). All studies were limited by retrospective designs, introducing potential selection and therapeutic bias. Conclusions: In this meta-analysis, ADT was associated with an increased risk of AKI. No statistical association was found between GnRH agonist use and AKI. Orchiectomy presented a lower AKI risk compared to GnRH agonists. Further investigations, including post hoc analysis of randomized controlled trials, are warranted to confirm these findings. Characteristics of the included studies. Study Sample size (n) Mean age (years) ADT modality Control group AKI incidence (ADT) AKI incidence (control) Hazard ratio for GnRH use (95% CI) – sensitivity analyses Follow-up (years) Gandaglia 2014 31,408 78.6 GnRH agonist and Bilateral orchiectomy No ADT 30.7% 24.9% 1.73 (1.62-1.85) 10 Cardwell 2021 10,751 69.2 GnRH agonists, GnRH antagonist, oral antiandrogens, estrogens and orchiectomy No ADT 6.1% 5.2% 1.09 (0.88-1.34) 3.9 Sherer 2021 27,868 66 GnRH agonists, oral antiandrogens, and GnRH antagonist No ADT +Radiotherapy 10.5% 7.9% 1.25 (1.13-1.37) a 8.8 Lapi 2013 2,953 80.2 GnRH agonists, oral antiandrogens, GnRH agonists + oral antiandrogens, bilateral orchiectomy, estrogens, other combinations No ADT 9.2% 4.5% ≈ 1.54 (1.17-2.15) b / ≈ 1.04 (1.27-1.46) c 4.1 a Sensitivity analysis of all ADT modalities. b Adjusted analysis of current ADT modalities. c Adjusted analysis of past ADT modalities.

Time perception in cerebellar and basal ganglia stroke patients

Scientific Reports Annibale Antonioni, Emanuela Maria Raho, Mariagrazia Capizzi et al. Feb 10, 2025 DOI: 10.1038/s41598-025-89311-7

Prospective monitoring of prostate specific membrane antigen (PSMA) –positive recurrent prostate cancer: Preliminary data from 6 months PSMA follow-up.

Journal of Clinical Oncology Ravi Amrit Madan, Melissa Lauren Abel, Esther Mena et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.45

45 Background: PSMA imaging can identify recurrent prostate cancer after definitive surgery/radiation prior to detection on computed tomography (CT) or bone scan. Radiation to PSMA+ findings is common but lacks clear data demonstrating long term benefit. PSMA+ recurrent prostate cancer (PSMArpc) is often defined and treated as metastatic castration sensitive prostate cancer (mCSPC), yet PSMA imaging alone as an eligibility criteria was never studied in the mCSPC trials. PSMArpc requires better understanding to define at-risk patients (pts). Methods: NCT05588128 enrolls pts after definitive and possibly salvage therapies. Pts are required to be 1 year removed from definitive therapy with a PSA≥0.5 ng/ml, testosterone≥100 ng/dL, and negative CT/bone scans. Lymph nodes (LNs) up to 1.5 cm and prior therapies are permitted. At enrollment pts have a baseline PSMA, which is repeated every 6 months (mos) if positive. If negative PSMA is done annually. CT and bone scans are also repeated annually. Pts are allowed to have radiation therapy or systemic therapies for ≤6 mos and remain on-study. Up to 350 pts will be enrolled and followed for up to 5 years. Results: Over 100 pts have enrolled since 3/2023 and 73 pts were evaluable after the 6-month PSMA scan/follow-up. The pts had a median age of 71 years, PSA=2.8, PSA doubling time=11.1 mos (30% less than 6 mos). In an overlapping descriptive analysis 10 pts were PSMA- and 15 pts had only local disease. For PSMA+ LNs, 15 pts had 1 LN, 8 pts had 2-3 LNs+, 4 pts had 4 LNs+, and 16 pts had 5+ LNs. 6 pts had bone findings, but negative bone scan. 3 pts had PSMA+ serosal nodules. After baseline PSMA 3 pts had radiation to solitary LNs, only 1 resolved/PSA declined. 1 pt elected androgen deprivation and 1 pt had salvage radiation. 4 pts enrolled in a clinical study at the NCI without androgen deprivation. At 6 mos PSMA scan only 2 pts had metastatic disease, both with bone scan findings, no pts had LNs beyond eligibility size criteria, and no pts had new visceral findings. Conclusions: These preliminary data from an ongoing study suggest PSMArpc is an indolent disease process and pts are at limited risk for clinically relevant progression within 6 mos. This study continues to accrue at the NCI and will seek to better define high-risk PSMArpc. These preliminary data may better inform the risks/benefits of aggressive treatment of PSMArpc and clinical studies in PSMArpc. Clinical trial information: NCT05588128 .

Circulating tumor cell expression analysis from the phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects (BRCAAway).

Journal of Clinical Oncology Zachery R Reichert, Maha H. A. Hussain, Jennie L Lovett et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.199

199 Background: Approximately 25% of patients (pts) with prostate cancer have deleterious germline/somatic homologous recombination repair mutations (HRRm). BRCAAway found the combination of an androgen receptor (AR) pathway inhibitor (ARPi) and poly(ADP-ribose) polymerase inhibitor (PARPi) as first-line therapy in pts with mCRPC and BRCA1/2 and/or ATM alterations to demonstrate longer progression-free survival (PFS) vs either agent alone or sequentially. Understanding AR signaling in HRRm (BRCA2 altered especially) versus intact patients and how they relate to response is unknown and may offer insights to mechanisms of resistance/sensitivity. Methods: Pts were randomized 1:1:1 to Arm1: abiraterone (1,000 mg)/prednisone (5 mg BID) (Abi), Arm2: olaparib (300 mg BID) (Ola), or Arm3: abiraterone/prednisone + olaparib (Abi + Ola). Internally analyzed, pooled circulating tumor cells (CTCs) were captured via bead-based EPCAM antibody with subsequent RT-PCR for gene expression profiling. Pretreatment samples from 47 pts across the three arms were compared to a historical CRPC cohort for difference and evaluated for a predictor of poor PSA response (stable PSA or progression by PCWG3). Results: A high probability of CTCs was found in 23 of 47 pts (48.9%, 11 Abi, 6 Ola, 6 Abi + Ola). In comparison to historical mCRPC pts, those with HRRm did not segregate from DNA repair intact pts regarding AR signaling. Also, PSA responders did not segregate from non-responders. Focusing on those with BRCA2 HRRm (20/23, 10 Abi, 5 Ola, 5 Abi+Ola), lack of PSA response was seen in 6/20 (30%). Combining the monotherapy cohorts, higher AR expression (median 22 for nonresponders and 15 for responders) correlated with lack of PSA response (unpaired t-test p=0.03), while ARV7 (median 18 vs 12) did not but may suffer from underpowering (p=0.20). Interestingly, the Abi+Ola cohort had a median AR expression closer to nonresponders (21.3), yet all 5 responded. Conclusions: Enriched CTC gene profiles from BRCAAway study pts prior to therapy in all arms appear similar to non HRRm mutant pts, supporting that the AR signaling pathway is consistently altered in mCRPC regardless of HRR status. For those with BRCA2 related HRRm, high AR expression associates with poor monotherapy response (Abi or Ola), but not the combination (Abi+Ola), suggesting the combination may rescue patients with AR addiction. Clinical trial information: NCT03012321 . BRCA2 cohort only (n=20) PSA ResponderMedian Gene Expression (IQR 25th/75th ) PSA NonResponder Median Gene Expression (IQR 25th/75th ) Unpaired t-test Monotherapy Cohort (Abi or Ola, n=15) AR 15.0 (13.7, 21.0) 22.0 (20.3, 23.2) P=0.03 ARV7 12.0 (3.8, 16) 18.0 (13.1, 19.7) P=0.20 Combination Cohort (Abi+Ola, n=5) AR 21.3 (20.3, 22.7) None N/A ARV7 16.3 (1.8, 18.0) None N/A